Touchlight signs license agreement with Voyager for use of Touchlight’s DNA technology in Voyager’s capsid discovery platform Published: 15 November 2022 Touchlight, an innovation-driven CDMO enabling the development of genetic…
Read More
Sarah Moore In this white paper, authored by Dr Sarah Moore, Head of Gene Therapy Discovery, Touchlight, we discuss major challenges and present approaches to improve overall functional titre, through…
Read More
Lonza and Touchlight collaborate on end-to-end mRNA offering Published: 6 September 2022 Collaboration expands Lonza’s end-to-end offering for mRNA manufacturing with additional, differentiated source of DNA raw material, Touchlight’s doggybone…
Read More
Satish Muchakayala Antimicrobial resistance (AMR) is a global health threat and a complex problem that requires a united multisectoral approach. In the interest of patients and environmental safety, regulators around…
Read More
Touchlight signs patent license agreement with Pfizer for the use of dbDNA for the manufacture of mRNA-based vaccines, therapeutics and gene therapies Published: 6 July 2022 Pfizer and Touchlight agree to patent license…
Read More
SARAH MOORE & MARIA BARREIRA With contribution by Helen Horton and Claire KerridgeTraditional bacterial fermentation techniques used to manufacture plasmid are time-consuming, expensive, and inherently unstable. The production of sufficient…
Read More
AskBio and Touchlight Restructure Joint Venture Published: 8 February 2022 Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, and Touchlight,…
Read More
Plasmid DNA Challenges In Advanced Therapy Manufacturing Published: 24 November 2021 Dr Tommy Duncan Introducing doggybone DNA, a synthetic antibiotic-free DNA vector. The genetic medicine revolution is underway. Just 18…
Read More
Touchlight Ranked Number Four Fastest Growing Technology Company in the UK in the 2021 Deloitte Technology Fast 50 Published: 22 November 2021 headline Touchlight, a biotechnology company pioneering enzymatic DNA…
Read More
Touchlight raises £42 million ($58 million) to meet unprecedented global DNA demand Published: 11 March 2021 Touchlight raises £42 million ($58 million) to meet unprecedented global DNA demand Completed facility…
Read More
